Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00642278 · ClinicalTrials.gov registry record · Phase 2
An Efficacy, Safety, and Tolerability Study of Canagliflozin (JNJ-28431754) in Patients With Type 2 Diabetes
A Phase 2 study, sponsored by Johnson & Johnson Pharmaceutical Research & Development, L.L.C..
- Completed
- Registry status
- Phase 2
- Development phase
- 451
- Enrollment target
NCT00642278: Completed Phase 2 study, sponsored by Johnson & Johnson Pharmaceutical Research & Development, L.L.C..
NCT00642278 is a Phase 2 study that has completed, run by Johnson & Johnson Pharmaceutical Research & Development, L.L.C.. The registered enrollment target is 451 participants, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (239% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00642278, a Phase 2 study, has completed, sponsored by Johnson & Johnson Pharmaceutical Research & Development, L.L.C..
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 451 participants
- Enrollment target
Study Summary
The purpose of this study is to evaluate the effectiveness, safety, and tolerability of JNJ-28431754 compared with placebo in patients with type 2 diabetes.
Primary Outcome
The table below shows the mean change in HbA1c from Baseline to Week 12 for each treatment group. The statistical analyses show the treatment differences (ie, each canagliflozin or sitagliptin group minus placebo) in the least-squares mean change.
Interventions
- DRUG Placebo
- DRUG Sitagliptin
- DRUG Canagliflozin (JNJ-28431754)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 451 participants |
| Start Date | 2008-04 |
| Est. Completion | 2009-01 |
| Phase | Phase 2 |
What the finished NCT00642278 record still lists
NCT00642278 is an interventional study that assigns participants to a tested intervention. The registered 451 participants enrollment target is mid-sized for trials with a published cap, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (239% higher).
The record links to 0 conditions, and to 3 interventions - of which Placebo is the first listed.
NCT00642278 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00642278 about?
NCT00642278 is a clinical study titled "An Efficacy, Safety, and Tolerability Study of Canagliflozin (JNJ-28431754) in Patients With Type 2 Diabetes". The purpose of this study is to evaluate the effectiveness, safety, and tolerability of JNJ-28431754 compared with placebo in patients with type 2 diabetes.
What is the current status of trial NCT00642278?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 451 participants. The study started on 2008-04. Estimated completion is 2009-01.
What interventions are being tested in trial NCT00642278?
The interventions under investigation include: Placebo (DRUG), Sitagliptin (DRUG), Canagliflozin (JNJ-28431754) (DRUG).
Who is sponsoring clinical trial NCT00642278?
This trial is sponsored by Johnson & Johnson Pharmaceutical Research & Development, L.L.C., which has 102 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00642278's enrollment target sits among peer trials
451 87th of 2000 higher than 1,914 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05676255 · 452 participants · Phase 2
The Breast Cancer Survivors and Partners Online Research Together (SUPORT) Project
- NCT05703178 · 452 participants · Phase 3
Web-based Pain Coping Skills Training for Breast Cancer Survivors With AI-Associated Arthralgia
- NCT00515060 · 450 participants
Psychophysical Studies of Cancer Therapy Pain
- NCT01257269 · 450 participants
Genotype and Phenotype Correlation in Hereditary Thrombotic Thrombocytopenic Purpura (Upshaw-Schulman Syndrome)
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia